NCT07283185

Brief Summary

MRCP and EUS are diagnostically equivalent in detecting CBD stones among patients with intermediate risk, as shown in a landmark RCT. However, MRI-based imaging is power-intensive, requiring large infrastructure and long scan durations. EUS, a less energy-consuming and portable procedure, has the added advantage of enabling same-session ERCP, reducing the need for repeat procedures.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started Dec 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Dec 2025Nov 2026

Study Start

First participant enrolled

December 1, 2025

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

December 2, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 15, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

January 6, 2026

Status Verified

October 1, 2025

Enrollment Period

11 months

First QC Date

December 2, 2025

Last Update Submit

January 4, 2026

Conditions

Choledocholithiasis

Outcome Measures

Primary Outcomes (1)

  • Total kg CO₂e per procedure for EUS vs MRCP.

    Total kg CO₂e per procedure for EUS vs MRCP.

    12 months

Secondary Outcomes (1)

  • Emissions

    12 months

Study Arms (2)

EUS

Patients scheduled for Endoscopic Ultrasound

MRCP

Patients scheduled for Magnetic Resonance Cholangiopancreatography

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients (\>18 years - 80years) with suspected choledocholithiasis and classified as intermediate risk per ESGE guidelines, undergoing either EUS or MRCP.

You may qualify if:

  • Age ≥18 years
  • Intermediate likelihood of CBD stone (per ESGE)
  • Undergoing either MRCP or EUS for evaluation

You may not qualify if:

  • High or low likelihood category (per ESGE)
  • Undergoing both MRCP and EUS simultaneously
  • Contraindications to either modality

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AIG Hospitals

Hyderabad, Telangana, 500032, India

RECRUITING

Related Publications (4)

  • • McAlister S et al. Radiology. 2021. Imaging footprint

    RESULT

  • • Lenzen M et al. Lancet Planet Health. 2020. Health care emissions

    RESULT

  • • Rughwani H et al. Gut. 2025. Carbon footprint of GIE

    RESULT

  • • Jagtap N et al. Gut. 2022. EUS versus MRCP RCT

    RESULT

MeSH Terms

Conditions

Choledocholithiasis

Condition Hierarchy (Ancestors)

Common Bile Duct DiseasesBile Duct DiseasesBiliary Tract DiseasesDigestive System DiseasesCholelithiasis

Central Study Contacts

Dr.Hardik Rughwani

CONTACT

9426928600dr.hardikr@aighospitals.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 2, 2025

First Posted

December 15, 2025

Study Start

December 1, 2025

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

January 6, 2026

Record last verified: 2025-10

Locations

IN(1)